REGN5715 / Regeneron - LARVOL DELTA

A single dose of a combination of Bet v 1 antibodies provides durable efficacy in the reduction of allergic rhinitis symptoms for up to 3 months in patients with moderate-severe birch pollen allergy (EAACI 2024) - "Birch allergic patients were randomized 1:1:1:1 to receive either Bet v 1 antibodies (REGN5713/14/15 [3-mAb], REGN5713/15 [2-mAb] or REGN5715 [1-mAb]) or placebo [administered subcutaneously] in this phase II, randomized, double-blind, placebo-controlled study...A single dose of a combination of Bet v 1 antibodies [3-mAb or 2-mAb] provides robust and durable reduction in birch pollen-induced allergic nasal symptoms for up to 3 months, which has the potential to provide coverage for the natural birch season. These data support the need for blockade of more than one epitope for optimal efficacy in birch allergy."

Clinical • Allergic Rhinitis • Allergy • Immunology • Inflammation

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants (clinicaltrials.gov) - P2 | N=218 | Completed | Sponsor: Regeneron Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants (clinicaltrials.gov) - P2 | N=218 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Efficacy of Anti-Allergen Therapeutics in a Preclinical Model of Allergic Anaphylaxis Correlates with Symptomatic Relief in Allergic Patients (EAACI 2022) - "Blockade of individual mAbs versus mAb cocktails confirms optimal blocking efficacy of Fel d 1 mAb cocktail (REGN1908-1909) compared with either single mAb; Bet v 1 triple mAb cocktail (REGN5713-5714-5715) compared with single mAb (REGN5715) or dual mAb cocktail (REGN5713-5715). Conclusion Blockade of mast cell degranulation in the PCA mouse model correlates to efficacy in clinical settings, validating the model as a useful tool for selection of efficacious anti-allergen therapeutics."

Preclinical • Allergy • Immunology

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals

New P2 trial • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology